294 related articles for article (PubMed ID: 18422560)
1. Anti tumour necrosis-alpha therapy increases the number of FOXP3 regulatory T cells in children affected by Crohn's disease.
Ricciardelli I; Lindley KJ; Londei M; Quaratino S
Immunology; 2008 Oct; 125(2):178-83. PubMed ID: 18422560
[TBL] [Abstract][Full Text] [Related]
2. Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab.
Li Z; Arijs I; De Hertogh G; Vermeire S; Noman M; Bullens D; Coorevits L; Sagaert X; Schuit F; Rutgeerts P; Ceuppens JL; Van Assche G
Inflamm Bowel Dis; 2010 Aug; 16(8):1299-310. PubMed ID: 20196149
[TBL] [Abstract][Full Text] [Related]
3. FoxP3(+)CD4(+)CD25(+) T cells with regulatory properties can be cultured from colonic mucosa of patients with Crohn's disease.
Kelsen J; Agnholt J; Hoffmann HJ; Rømer JL; Hvas CL; Dahlerup JF
Clin Exp Immunol; 2005 Sep; 141(3):549-57. PubMed ID: 16045746
[TBL] [Abstract][Full Text] [Related]
4. Therapy with anti-TNFα antibody enhances number and function of Foxp3(+) regulatory T cells in inflammatory bowel diseases.
Boschetti G; Nancey S; Sardi F; Roblin X; Flourié B; Kaiserlian D
Inflamm Bowel Dis; 2011 Jan; 17(1):160-70. PubMed ID: 20848510
[TBL] [Abstract][Full Text] [Related]
5. Expression of TIM-3, Human β-defensin-2, and FOXP3 and Correlation with Disease Activity in Pediatric Crohn's Disease with Infliximab Therapy.
Kim MJ; Lee WY; Choe YH
Gut Liver; 2015 May; 9(3):370-80. PubMed ID: 25071071
[TBL] [Abstract][Full Text] [Related]
6. FOXP3+ regulatory T-cell counts correlate with histological response in Crohn's colitis treated with infliximab.
Sloan S; Maxwell P; Salto-Tellez M; Loughrey MB
Pathol Int; 2014 Dec; 64(12):624-7. PubMed ID: 25354875
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumour necrosis factor therapy enhances mucosal healing through down-regulation of interleukin-21 expression and T helper type 17 cell infiltration in Crohn's disease.
Liu C; Xia X; Wu W; Wu R; Tang M; Chen T; Xu F; Cong Y; Xu X; Liu Z
Clin Exp Immunol; 2013 Jul; 173(1):102-11. PubMed ID: 23607532
[TBL] [Abstract][Full Text] [Related]
8. Anti-TNF Therapy Induces CD4+ T-Cell Production of IL-22 and Promotes Epithelial Repairs in Patients With Crohn's Disease.
Fang L; Pang Z; Shu W; Wu W; Sun M; Cong Y; Liu Z
Inflamm Bowel Dis; 2018 Jul; 24(8):1733-1744. PubMed ID: 29718341
[TBL] [Abstract][Full Text] [Related]
9. T2 enhances in situ level of Foxp3+ regulatory cells and modulates inflammatory cytokines in Crohn's disease.
Li G; Ren J; Wang G; Gu G; Hu D; Ren H; Hong Z; Wu X; Liu S; Li J
Int Immunopharmacol; 2014 Feb; 18(2):244-8. PubMed ID: 24369313
[TBL] [Abstract][Full Text] [Related]
10. Anti-TNF-alpha loss of response is associated with a decreased percentage of FoxP3+ T cells and a variant NOD2 genotype in patients with Crohn's disease.
Juanola O; Moratalla A; Gutiérrez A; Sempere L; Zapater P; Giménez P; Almenta I; Peiró G; González-Navajas JM; Such JF; Francés R
J Gastroenterol; 2015 Jul; 50(7):758-68. PubMed ID: 25500977
[TBL] [Abstract][Full Text] [Related]
11. Reduction of CD68+ macrophages and decreased IL-17 expression in intestinal mucosa of patients with inflammatory bowel disease strongly correlate with endoscopic response and mucosal healing following infliximab therapy.
Caprioli F; Bosè F; Rossi RL; Petti L; Viganò C; Ciafardini C; Raeli L; Basilisco G; Ferrero S; Pagani M; Conte D; Altomare G; Monteleone G; Abrignani S; Reali E
Inflamm Bowel Dis; 2013; 19(4):729-39. PubMed ID: 23448791
[TBL] [Abstract][Full Text] [Related]
12. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease.
Danese S; Sans M; Scaldaferri F; Sgambato A; Rutella S; Cittadini A; Piqué JM; Panes J; Katz JA; Gasbarrini A; Fiocchi C
J Immunol; 2006 Feb; 176(4):2617-24. PubMed ID: 16456024
[TBL] [Abstract][Full Text] [Related]
13. Flt3 ligand expands CD103⁺ dendritic cells and FoxP3⁺ T regulatory cells, and attenuates Crohn's-like murine ileitis.
Collins CB; Aherne CM; McNamee EN; Lebsack MD; Eltzschig H; Jedlicka P; Rivera-Nieves J
Gut; 2012 Aug; 61(8):1154-62. PubMed ID: 22068168
[TBL] [Abstract][Full Text] [Related]
14. Profiles of Lamina Propria T Helper Cell Subsets Discriminate Between Ulcerative Colitis and Crohn's Disease.
Li J; Ueno A; Fort Gasia M; Luider J; Wang T; Hirota C; Jijon HB; Deane M; Tom M; Chan R; Barkema HW; Beck PL; Kaplan GG; Panaccione R; Qian J; Iacucci M; Gui X; Ghosh S
Inflamm Bowel Dis; 2016 Aug; 22(8):1779-92. PubMed ID: 27243594
[TBL] [Abstract][Full Text] [Related]
15. Suppressive and Gut-Reparative Functions of Human Type 1 T Regulatory Cells.
Cook L; Stahl M; Han X; Nazli A; MacDonald KN; Wong MQ; Tsai K; Dizzell S; Jacobson K; Bressler B; Kaushic C; Vallance BA; Steiner TS; Levings MK
Gastroenterology; 2019 Dec; 157(6):1584-1598. PubMed ID: 31513797
[TBL] [Abstract][Full Text] [Related]
16. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis.
Baert FJ; D'Haens GR; Peeters M; Hiele MI; Schaible TF; Shealy D; Geboes K; Rutgeerts PJ
Gastroenterology; 1999 Jan; 116(1):22-8. PubMed ID: 9869598
[TBL] [Abstract][Full Text] [Related]
17. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease.
Van den Brande JM; Koehler TC; Zelinkova Z; Bennink RJ; te Velde AA; ten Cate FJ; van Deventer SJ; Peppelenbosch MP; Hommes DW
Gut; 2007 Apr; 56(4):509-17. PubMed ID: 17082252
[TBL] [Abstract][Full Text] [Related]
18. Peripheral regulatory T cells and serum transforming growth factor-β: relationship with clinical response to infliximab in Crohn's disease.
Di Sabatino A; Biancheri P; Piconese S; Rosado MM; Ardizzone S; Rovedatti L; Ubezio C; Massari A; Sampietro GM; Foschi D; Porro GB; Colombo MP; Carsetti R; MacDonald TT; Corazza GR
Inflamm Bowel Dis; 2010 Nov; 16(11):1891-7. PubMed ID: 20848485
[TBL] [Abstract][Full Text] [Related]
19. Death Receptor 3 Signaling Controls the Balance between Regulatory and Effector Lymphocytes in SAMP1/YitFc Mice with Crohn's Disease-Like Ileitis.
Li Z; Buttó LF; Buela KA; Jia LG; Lam M; Ward JD; Pizarro TT; Cominelli F
Front Immunol; 2018; 9():362. PubMed ID: 29545797
[TBL] [Abstract][Full Text] [Related]
20. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease.
Van den Brande JM; Braat H; van den Brink GR; Versteeg HH; Bauer CA; Hoedemaeker I; van Montfrans C; Hommes DW; Peppelenbosch MP; van Deventer SJ
Gastroenterology; 2003 Jun; 124(7):1774-85. PubMed ID: 12806611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]